Skip to NavigationSkip to content

Bayer buys hypertension drug rights from GSK

Published on 12/01/06 at 02:51pm

Bayer has bought the rights to market the hypertension drug telmisartan in a number of European markets from current licence holder GlaxoSmithKline.

Boehringer Ingelheim discovered telmisartan, and markets it in 84 countries globally under the brand name Micardis (and as Micardis Plus in combination with hydrochlorazide) including the UK.

Until now, the company has had two co-marketing partners in Europe - GSK and Bayer - but now Bayer is taking all the European co-marketing rights from GSK except Turkey.

GSK will also continue to co-market the drug with Boehringer in Brazil, South Korea, the Phillipines and Venezuela.

Boehringer's deal now includes marketing in France, Italy, Spain, Greece, Portugal and 22 smaller European markets. It already co-markets the drug with Bayer under the name of Kinzalmono in Germany, Belgium, the Netherlands, Switzerland and Finland.

"This agreement strengthens the existing relationship with Bayer, one of the international players in the cardiovascular area. It provides an excellent platform to increase awareness of a long-acting treatment option in a disease area where patients remain under-treated," said Albert Ros-Morte, corporate director marketing of Boehringer Ingelheims prescription business.








Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches